Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.
about
A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicityAspirin for primary prevention of cardiovascular diseaseEsomeprazole and aspirin fixed combination for the prevention of cardiovascular eventsExpert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapyInhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and DevelopmentProton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General PopulationAspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance.Patterns of multimorbidity in elderly veteransAssociation between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis.Proton pump inhibitors and the risk of adverse cardiac eventsProton pump inhibitors and vascular function: A prospective cross-over pilot studyProton pump inhibitors are associated with increased risk of development of chronic kidney disease.Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis.Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study.How May Proton Pump Inhibitors Impair Cardiovascular Health?Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.Inconsistencies surrounding the risk of adverse outcomes with concomitant use of clopidogrel and proton pump inhibitors.The clinical relevance of the clopidogrel-proton pump inhibitor interaction.Acute gastrointestinal bleeding after percutaneous coronary intervention.Adherence to guidelines for the prescribing of double and triple combinations of antithrombotic agents.Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care.Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients.Overcoming aspirin treatment failure in diabetes.Identifying determinants of variability to tailor aspirin therapy.A benefit-risk assessment of the use of proton pump inhibitors in the elderly.Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin.Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study.Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy.Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events.Frequency of nonsteroidal anti-inflammatory drug-associated ulcers.Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms.Inappropriate Use of Proton Pump Inhibitors in Elderly Patients Discharged from Acute Care Hospitals.Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population: A Nationwide Population-Based Study.Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.Pharmacovigilance using Clinical Text.A pharmacist's guide to the 2012 update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy.Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding--a cohort study of the effects of proton pump inhibitor use patterns.Long-term proton pump inhibitor use is associated with vascular calcification in chronic kidney disease: a cross-sectional study using propensity score analysis.Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study.
P2860
Q24615651-34C66583-AC08-41AB-894A-F80E8E3B55E7Q26774150-46B9A523-B040-4C25-B331-765193CF8A50Q26995752-1148169C-13CD-47F2-AE96-9AFE9EA42A1EQ26998331-370B9703-4D1D-4D2C-85E5-041CE66D3364Q28070134-383E24AB-50CB-4D22-943C-229DB4946F3CQ28548045-2BAF9168-41BA-427B-9209-DF9B2D84BAD6Q30457290-480355CF-4D92-4050-831A-7C9247BA99D2Q33767571-1ED24131-F240-4FE9-9481-B6E8296A906EQ34049889-22353B5A-1E33-4FCB-9344-90C354C3E846Q34510524-493A9DD1-632F-4AE5-B52D-3CAA598D5AA6Q35081085-D701C0BC-5DA4-492E-889F-116E1D91323AQ36067712-B22E6671-D88B-4F99-8C98-0BA87AEFD53EQ36094152-46375DCA-82CA-4DBD-B766-D5D6BE962897Q36117874-E7465DBC-E310-4E59-9E37-34CF56BB6936Q36846899-A806D112-14CC-435C-8EFE-E2766714163EQ36892867-34274EDE-0089-4824-B77B-604E948422A1Q37336634-EDC3657F-A799-487D-8409-827724884A34Q37979853-10773D50-3E87-4B64-8DE0-FA6F1BAA1C3CQ37986645-16DD997F-B6DA-4A91-BF8D-5D4979F1FF0FQ37989162-887407F5-3CDA-44E8-A1BB-84A7B279CD94Q38017567-B337B8FB-C124-4783-BEE4-6A651B9BA157Q38026979-6369C039-938B-4CD4-9B54-563E27DC1791Q38030989-898623B7-43AF-44D1-8283-A51EC2514FA8Q38055245-F08C1026-2CD5-4716-BD6A-F1EFB524999CQ38087384-5870C131-F12B-4A9B-B009-B3125771C0EDQ38196383-48B9C6CD-BF1D-4F28-B1AB-26590E95CAC1Q38237417-3D47769F-6F8B-471C-A23C-FC83D0E2B5BFQ38439626-7AB8D43E-17C8-47E9-8CCA-8C4965A8B8F0Q38806725-8903BC67-5C2C-4ABF-A0C3-BFA314EEA202Q39482145-A3310D3B-7C86-4B1C-8484-A3F27401555AQ39611144-58E7F9FD-CB3F-4641-B3EA-709418DA2E7EQ39658839-EADE1731-55C2-4F5B-A6E6-7AC4687C27A5Q39702517-0C42FBF4-906E-4727-99B9-6A6DC59D8CCFQ40248473-2FD75623-ECBB-4417-B219-D5CB7AC9FBB4Q41725713-293AEED6-5398-4A8B-BB11-F5E1DE76F1E5Q42925545-87AC3535-6145-455B-B1D6-642BE4E1C96EQ43194487-666CBE7F-59E2-4BFE-B460-5C8E370AC14AQ44665525-3016EC58-C35B-420F-9036-7A9A30B74F74Q44820678-46F093F4-5F55-4BE1-AA7B-D7C5026DAE35Q45386150-00805E19-08F8-47BC-AD35-A6271597BE31
P2860
Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Proton pump inhibitor use and ...... ropensity score matched study.
@ast
Proton pump inhibitor use and ...... ropensity score matched study.
@en
Proton pump inhibitor use and ...... ropensity score matched study.
@nl
type
label
Proton pump inhibitor use and ...... ropensity score matched study.
@ast
Proton pump inhibitor use and ...... ropensity score matched study.
@en
Proton pump inhibitor use and ...... ropensity score matched study.
@nl
prefLabel
Proton pump inhibitor use and ...... ropensity score matched study.
@ast
Proton pump inhibitor use and ...... ropensity score matched study.
@en
Proton pump inhibitor use and ...... ropensity score matched study.
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
Proton pump inhibitor use and ...... ropensity score matched study.
@en
P2093
Jan Kyst Madsen
Jesper Lindhardsen
Mette Charlot
Ole Ahlehoff
P2860
P356
10.1136/BMJ.D2690
P407
P50
P577
2011-05-11T00:00:00Z